Which stage of myeloma should I take Pomalidomide?

Pomalidomide (Pomalidomide) is a thalidomide analog immunomodulator. In February 2013, the U.S. Food and Drug Administration (FDA) approved pomalidomide for the treatment of patients with multiple myeloma (MM) who have received two or more prior treatments (including lenalidomide and bortezomib) and have disease progression within 60 days of completion of the last treatment.

A phase III, multicenter, randomized, open-label study in patients with relapsed MM resistant to lenalidomide and bortezomib compared pomalidomide plus low-dose dexamethasone (POM+LoDEX) with high-dose dexamethasone alone The recommended starting dose of dexamethasone (HiDEX) is 4 mg once a day, and the oral dose of dexamethasone is 40 mg once a week on days 1-21 of repeated 28-day cycles. Studies have shown that pomalidomide is a third-line drug for patients with relapsed or refractory MM, providing an oral administration option for these patient groups who have failed previous treatments.

Pomalidomide, independently developed in China, has been launched domestically and has now entered the scope of medical insurance. The price of domestically produced Pomalidomide may be around RMB 4,000 per box, while the Turkish version sold overseas may be priced around RMB 15,000 per box (the price may fluctuate due to exchange rates), which is relatively expensive. There are also cheaper generic drugs produced in other countries overseas. The price of each box produced by a Lao pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to the exchange rate). The ingredients of foreign generic drugs, domestically produced drugs and foreign original drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.